ZyVersa Therapeutics Inc. - רווח למניה ב-12 החודשים האחרונים ZVSA

ZyVersa Therapeutics (ZVSA) is expanding its inflammasome inhibitor portfolio by scaling VAR 200 research for expansion into nephropharmaceuticals. The GURU.Markets portal features a chart of the annual growth of basic net income per share (ttm), where the -380.40 level captures the latest values. Patent protection for unique drugs ensures pricing power, while isolation from macroeconomic trends transforms the company into a reliable defensive asset.
פילוחי מדדים פיננסיים ומדדי שוק עבור ZyVersa Therapeutics (ZVSA)

This indicator measures the rate of change in net earnings per share over the last 12 months relative to the same period last year. By analyzing the historical EPS YoY TTM trend, an investor separates market noise from actual business expansion. The metric is sensitive to operational efficiency and the volume of capital expenditures. For ZyVersa Therapeutics (ZVSA), this confirms the viability of a lean management model. Minimizing headcount and outsourcing research via CROs allow for expense optimization, directly impacting the bottom line.